TABLE 1.
Clinicopathological characteristics of gastric cancer.
| Clinicopathological characteristic | N | Percentage (%) | |
|---|---|---|---|
| Gender | Male | 33 | 73.3 |
| Female | 12 | 26.7 | |
| Age | Median | 67 | |
| Range | 36–85 | ||
| Metastatic organs | 1 | 27 | 60.0 |
| 2 | 11 | 24.4 | |
| ≥3 | 7 | 15.6 | |
| Previous lines of treatment | 0 | 3 | 6.7 |
| 1 | 13 | 28.9 | |
| 2 | 29 | 64.4 | |
| Regimens | |||
| ICI monotherapy | 7 | 15.6 | |
| Pembrolizumab | 3 | ||
| Camrelizumab | 2 | ||
| Toripalimab | 2 | ||
| Chemotherapy plus ICIs | 5 | 11.1 | |
| Metronomic capecitabine | Camrelizumab | 5 | |
| Targeted therapy plus ICIs | 33 | 73.3 | |
| Apatinib | Camrelizumab | 15 | |
| Nivolumab | 2 | ||
| Sintilimab | 10 | ||
| Lenvatinib | Pembrolizumab | 3 | |
| Regorafenib | Nivolumab | 2 | |
| Trastuzumab | Sintilimab | 1 | |
| Cycles | Median | 5 | |
| Range | 2–26 | ||